References
- Finegold SM. Treatment of anaerobic infections: an overview. Scand J Infect Dis (Suppl) 1985: 46: 89
- Garb JL, Brown RB, Garb JR, et al. Differences in etiology of pneumonias in nursing home and community patients. JAMA 1978: 240(20): 2169–72
- Gross PA, Neu HC, Aswapokee P, et al. Deaths from nosocomial infections: experience in a university hospital and a community hospital. Am J Med 1980: 68(2): 219–23
- Quintiliani R, Klimek JJ, Nightingale CH. Restriction policies for therapy with combination antibiotics. (Editorial) J Infect Dis 1986: 153(4): 645–9
- Diaz Mitoma F, Harding GK, Louie TJ, et al. Prospective randomized comparison of imipenem/cilastatin and cefotaxime for treatment of lung, soft tissue, and renal infections. Rev Infect Dis 1985:7(Suppl 3): S452–7
- File TM Jr, Tan JS, Salstrom SJ, et al. Timentin vs piperacillin or moxalactam in the therapy of acute bacterial infections. Antimicrob Agents Chemother 1984: 26(3): 310–3
- Trenholme GM, Pottage JC Jr, Karakusis PH. Use of ceftazidime in the treatment of nosocomial lower respiratory infections. Am J Med 1985: 79(2A): 32–6
- Roselle GA, Bode R, Hamilton B, et al. Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid. Antimicrob Agents Chemother 1985: 27(3): 291–6
- Schwigon CD, Hulla FW, Schulze B, et al. Timentin in the treatment of nosocomial bronchopulmonary infections in intensive care units. J Antimicrob Chemother 1986: 17(Suppl C): 115–22
- McKellar PP. Treatment of community-acquired pneumonias. Am J Med 1985: 79(2A): 25–31
- Richmond MH, Sykes RB. The beta-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol 1973: 9: 31–88
- Acar JF. Therapy for lower respiratory tract infections with imipenem/cilastatIn: a review of worldwide experience. Rev Infect Dis 1985: 7(Suppl 3): S513–7
- Shah PM. Clinical experience with imipenem/cilastatIn: analysis of a multicenter study. Rev Infect Dis 1985: 7(Suppl 3): S471–5
- Winston DJ, McGrattan MA, Busuttil RW. Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother 1984: 26(5): 673–7
- Swabb EA, Cone CO, Muir JG. Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections. Rev Infect Dis 1985: 7(Suppl 4): S675–8
- Cox CE. Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria. Rev Infect Dis 1985:7(Suppl 4): S767–71
- Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with ever and neutropenia. New Engl J Med 1986: 315(9): 552–8